Reviva Pharmaceuticals Holdings, Inc. Payments to Acquire Restricted Investments
Reviva Pharmaceuticals Holdings, Inc. (RVPH) reported Payments to Acquire Restricted Investments of $736.92 thousand for the 9-month period ending 2020-11-30, per its 10-Q filed 2021-01-14.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireRestrictedInvestments · last filed 2021-01-14
- Reviva Pharmaceuticals Holdings, Inc. payments to acquire restricted investments for the quarter ending 2020-11-30 was $105.08K.
- Reviva Pharmaceuticals Holdings, Inc. payments to acquire restricted investments for the quarter ending 2020-08-31 was $421.00K.
- Reviva Pharmaceuticals Holdings, Inc. payments to acquire restricted investments for the quarter ending 2020-05-31 was $210.84K.
- Reviva Pharmaceuticals Holdings, Inc. payments to acquire restricted investments for the quarter ending 2020-02-29 was $567.18K.
- Reviva Pharmaceuticals Holdings, Inc. payments to acquire restricted investments for fiscal 2020 was $567.18K.
| Period end | Payments to Acquire Restricted Investments | Payments to Acquire Restricted Investments 1 month | Payments to Acquire Restricted Investments 3 month | Payments to Acquire Restricted Investments 5 month | Payments to Acquire Restricted Investments 6 month | Payments to Acquire Restricted Investments 6 month as first filed | Payments to Acquire Restricted Investments 8 month | Payments to Acquire Restricted Investments 9 month | Payments to Acquire Restricted Investments 11 month | Payments to Acquire Restricted Investments 12 month |
|---|---|---|---|---|---|---|---|---|---|---|
| 2020-11-30 | $105.08K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-01-14 | $526.09K derived: sum of 2 quarters · filed 2021-01-14 | $736.92K 10-Q · filed 2021-01-14 | $1.30M derived: sum of 4 quarters · filed 2021-01-14 | ||||||
| 2020-11-12 | $105.08K 10-Q · filed 2021-01-14 | |||||||||
| 2020-09-24 | $105.08K 10-Q · filed 2021-01-14 | |||||||||
| 2020-08-31 | $421.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-01-14 | $631.84K 10-Q · filed 2021-01-14 | $421.67K 10-Q · filed 2020-10-14 | $1.20M derived: sum of 3 quarters · filed 2021-01-14 | $1.20M derived: sum of 4 quarters · filed 2021-01-14 | |||||
| 2020-05-31 | $210.84K 10-Q · filed 2020-07-07 | $778.02K derived: sum of 2 quarters · filed 2020-07-07 | $778.02K derived: sum of 3 quarters · filed 2021-01-14 | $778.02K derived: sum of 4 quarters · filed 2021-01-14 | ||||||
| 2020-05-21 | $210.84K 10-Q · filed 2020-07-07 | |||||||||
| 2020-02-29 | $567.18K derived: 10-K 12 month − 10-Q 9 month · filed 2020-05-04 | $567.18K derived: sum of 2 quarters · filed 2021-01-14 | $567.18K derived: sum of 3 quarters · filed 2021-01-14 | $567.18K 10-K · filed 2020-05-04 | ||||||
| 2020-02-18 | $567.18K 10-K · filed 2020-05-04 | |||||||||
| 2020-02-10 | $567.18K 10-Q · filed 2020-10-14 | |||||||||
| 2019-11-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-01-14 | $0.00 derived: sum of 2 quarters · filed 2021-01-14 | $0.00 10-Q · filed 2021-01-14 | |||||||
| 2019-08-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-10-14 | $0.00 10-Q · filed 2020-10-14 | ||||||||
| 2019-05-31 | $0.00 10-Q · filed 2020-07-07 | |||||||||
| 2019-02-28 | $64.52M 10-K · filed 2020-05-04 | |||||||||
| 2019-02-10 | $567.18K 10-Q · filed 2021-01-14 | |||||||||
| 2018-11-30 | $64.52M 10-Q · filed 2020-01-10 | |||||||||
| 2018-08-31 | $64.52M 10-Q · filed 2019-10-08 | |||||||||
| 2018-08-30 | $64.52M 10-Q · filed 2020-01-10 | $64.52M 10-Q · filed 2019-07-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |